- Home
- VMD vs CTNM Comparison
VMD vs CTNM Comparison
Compare VMD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- CTNM
- Stock Information
- Founded
- VMD 2006
- CTNM 2009
- Country
- VMD United States
- CTNM United States
- Employees
- VMD N/A
- CTNM N/A
- Industry
- VMD
- CTNM
- Sector
- VMD
- CTNM
- Exchange
- VMD Nasdaq
- CTNM Nasdaq
- Market Cap
- VMD 280.4M
- CTNM 248.7M
- IPO Year
- VMD N/A
- CTNM 2024
- Fundamental
- Price
- VMD $6.87
- CTNM $11.21
- Analyst Decision
- VMD
- CTNM Strong Buy
- Analyst Count
- VMD 0
- CTNM 5
- Target Price
- VMD N/A
- CTNM $22.20
- AVG Volume (30 Days)
- VMD 177.7K
- CTNM 201.6K
- Earning Date
- VMD 11-05-2025
- CTNM 11-05-2025
- Dividend Yield
- VMD N/A
- CTNM N/A
- EPS Growth
- VMD 47.14
- CTNM N/A
- EPS
- VMD 0.34
- CTNM N/A
- Revenue
- VMD $240,884,000.00
- CTNM N/A
- Revenue This Year
- VMD $19.22
- CTNM N/A
- Revenue Next Year
- VMD $17.51
- CTNM N/A
- P/E Ratio
- VMD $20.41
- CTNM N/A
- Revenue Growth
- VMD 17.11
- CTNM N/A
- 52 Week Low
- VMD $5.93
- CTNM $3.35
- 52 Week High
- VMD $9.81
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- VMD 51.33
- CTNM 55.51
- Support Level
- VMD $6.71
- CTNM $10.65
- Resistance Level
- VMD $7.04
- CTNM $12.14
- Average True Range (ATR)
- VMD 0.20
- CTNM 0.97
- MACD
- VMD 0.01
- CTNM -0.23
- Stochastic Oscillator
- VMD 67.92
- CTNM 32.20
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.